Institute of Good Manufacturing Practices India

Global accredited training & certification provider

IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Positive results announced by RemeGen Ltd. for RC48 clinical trial in HER2-Positive Metastatic or Unresectable urothelial cancer


04th June 2019

Positive results pertaining to RC48 Phase II clinical trials were announced by RemeGen Ltd. The company had evaluated a potential new medicine for patients who have HER2-positive metastatic or unresectable urothelial cancer. These patients had undergone chemotherapy treatment earlier and had visceral metastasis.

51 percent confirmed objective response rate per independent central review was obtained from the results. Hemotoxicity, alopecia and hypothesia are the adverse events associated with common treatment.

RC-48 is a novel antibody-drug conjugate developed for the treatment of HER2-positive solid tumors. It includes a cathepsin cleavable linker, HER2-monoclonal antibody and monomethyl auristatin E as cytotoxic payload. It has an excellent safety profile as depicted in clinical trials. RC48 could be able to support patients whose cancer has progressed following the standard chemotherapy treatment and immune-oncology agents.

Urothelial carcinoma is a widespread cancer and RC48 is believed to be an efficient treatment for the patients. In spite of being a common form of bladder cancer, there is no breakthrough treatment for the disease so far. Cisplatin-based chemotherapy is the current therapeutic option which has high recurrence and mortality rate.


For further enquiries, write to or call us on:
info@igmpiindia.org/ +91 8587838177, +91 8130924488, 0120-2427175

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like